{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:43:29Z","timestamp":1789137809920,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Healthcare Denmark A\/S","award":["POP3 number DK2201120023"],"award-info":[{"award-number":["POP3 number DK2201120023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socioeconomic. Evidence on the socioeconomic implications of CGRP-mAbs is, however, limited. There is an increasing interest in supplementing evidence from randomised controlled trials (RCTs) with real-world evidence (RWE) to aid clinical decision making and inform decision making for migraine management. The objective of this study was to generate RWE on the health economic and socioeconomic implications of administering CGRP-mAbs to patients with chronic migraine (CM) and episodic migraine (high-frequency episodic migraine (HFEM), and low-frequency episodic migraine (LFEM)).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Real-world data (RWD) on Danish patients with CM, HFEM, and LFEM were collected via two Danish patient organisations and two informal patient networks and used in a tailored economic model. Treatment effects of CGRP-mAbs on health economic and socioeconomic outcomes were estimated using a sub-sample of patients with CM who receive CGRP-mAb treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 362 patients (CM: 199 [55.0%], HFEM: 80 [22.1%], LFEM: 83 [22.9%]) were included in the health economic model (mean age 44.1\u2009\u00b1\u200911.5, 97.5% female, 16.3% received treatment with CGRP-mAbs), and 303 patients were included in the socioeconomic model (15.2% received treatment with CGRP-mAbs). Health economic savings from initiating CGRP-mAb treatment totalled \u20ac1,179 per patient with CM per year on average (HFEM: \u20ac264, LFEM: \u20ac175). Socioeconomic gains from initiating CGRP-mAb treatment totalled an average gross domestic product (GDP) gain of \u20ac13,329 per patient with CM per year (HFEM: \u20ac10,449, LFEM: \u20ac9,947).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicate that CGRP-mAbs have the potential to reduce both health economic expenditures and the socioeconomic burden of migraine. Health economic savings are used as a basis for health technology assessments (HTAs) of the cost-effectiveness of new treatments, which implies that important socioeconomic gains may not be given enough importance in decision making for migraine management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-023-03302-7","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T07:02:07Z","timestamp":1688367727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine"],"prefix":"10.1186","volume":"23","author":[{"given":"Nikolaj","family":"Siersb\u00e6k","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e6rke","family":"Kilsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jervelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bendtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"3302_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376.","journal-title":"N Engl J Med"},{"key":"3302_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-018-0946-z","volume":"19","author":"P Martelletti","year":"2018","unstructured":"Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain. 2018;19:115. https:\/\/doi.org\/10.1186\/s10194-018-0946-z.","journal-title":"J Headache Pain"},{"key":"3302_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"key":"3302_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, et al. Cost of healthcare for patients with migraine in five european countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain. 2012;13:361\u201378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7.","journal-title":"J Headache Pain"},{"key":"3302_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703\u201311. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x.","journal-title":"Eur J Neurol"},{"key":"3302_CR6","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1177\/0333102418796842","volume":"38","author":"M Sussman","year":"2018","unstructured":"Sussman M, Benner J, Neumann P, Menzin J. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018;38:1644\u201357. https:\/\/doi.org\/10.1177\/0333102418796842.","journal-title":"Cephalalgia"},{"key":"3302_CR7","doi-asserted-by":"publisher","unstructured":"Cohen F, Yuan H, Silberstein SD. (2022) Calcitonin gene-related peptide (CGRP)-Targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs. https:\/\/doi.org\/10.1007\/s40259-022-00530-0.","DOI":"10.1007\/s40259-022-00530-0"},{"key":"3302_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40120-021-00303-x","volume":"11","author":"H Autio","year":"2021","unstructured":"Autio H, Purmonen T, Kurki S, et al. Erenumab decreases headache-related sick leave days and Health Care visits: a Retrospective Real-World Study in Working patients with migraine. Neurol Ther. 2021;11:223\u201335. https:\/\/doi.org\/10.1007\/s40120-021-00303-x.","journal-title":"Neurol Ther"},{"key":"3302_CR9","volume-title":"Medicinr\u00e5dets samling af vurderinger af anti-CGRPantistoffer til behandling af kronisk migr\u00e6ne, herunder kriterier for opstart, monitorering og seponering","author":"Danish Medicines Council","year":"2021","unstructured":"Danish Medicines Council. Medicinr\u00e5dets samling af vurderinger af anti-CGRPantistoffer til behandling af kronisk migr\u00e6ne, herunder kriterier for opstart, monitorering og seponering. Denmark: Danish Medicines Council; 2021."},{"key":"3302_CR10","unstructured":"NICE. (2022) Recommendations | Fremanezumab for preventing migraine | Guidance. https:\/\/www.nice.org.uk\/guidance\/ta764\/chapter\/1-Recommendations. Accessed 10 May 2022."},{"key":"3302_CR11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"key":"3302_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cpt.2479","volume":"111","author":"P Arlett","year":"2022","unstructured":"Arlett P, Kjaer J, Broich K, Cooke E. Real-world evidence in EU Medicines Regulation: enabling Use and establishing value. Clin Pharmacol Ther. 2022;111:21\u20133. https:\/\/doi.org\/10.1002\/cpt.2479.","journal-title":"Clin Pharmacol Ther"},{"key":"3302_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2500\/aap.2021.42.200127","volume":"42","author":"AJ Castaldo","year":"2021","unstructured":"Castaldo AJ, Jervelund C, Corcoran D, et al. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema. Allergy and Asthma Proceedings. 2021;42:108\u201317. https:\/\/doi.org\/10.2500\/aap.2021.42.200127.","journal-title":"Allergy and Asthma Proceedings"},{"key":"3302_CR14","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society. (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"key":"3302_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s40122-021-00331-3","volume":"10","author":"P Pozo-Rosich","year":"2021","unstructured":"Pozo-Rosich P, Lucas C, Watson DPB, et al. Burden of migraine in patients with preventive treatment failure attending european Headache specialist Centers: real-world evidence from the BECOME study. Pain Ther. 2021;10:1691\u2013708. https:\/\/doi.org\/10.1007\/s40122-021-00331-3.","journal-title":"Pain Ther"},{"key":"3302_CR16","unstructured":"EMA. (2018) Aimovig. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aimovig. Accessed 10 Jun 2022."},{"key":"3302_CR17","unstructured":"EMA. (2019) Ajovy. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy. Accessed 10 Jun 2022."},{"key":"3302_CR18","unstructured":"EMA. (2018) Emgality. In: European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/emgality. Accessed 10 Jun 2022."},{"key":"3302_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/head.13421","volume":"58","author":"SD Silberstein","year":"2018","unstructured":"Silberstein SD, Lee L, Gandhi K, et al. Health care resource utilization and migraine disability along the Migraine Continuum among Patients treated for Migraine. Headache. 2018;58:1579\u201392. https:\/\/doi.org\/10.1111\/head.13421.","journal-title":"Headache"},{"key":"3302_CR20","doi-asserted-by":"crossref","unstructured":"Danish Medicine Information A\/S (Dansk L\u00e6gemiddel Information A\/S). (2022) Information regarding medicine (Information om medicin). https:\/\/pro.medicin.dk\/. Accessed 11 May 2022.","DOI":"10.1002\/cam4.3998"},{"key":"3302_CR21","unstructured":"Danish Health Data Authority (Sundhedsdatastyrelsen). (2022) DRG rates 2022 (DRG-takster 2022). https:\/\/sundhedsdatastyrelsen.dk\/da\/afregning-og-finansiering\/takster-drg\/takster-2022. Accessed 11 May 2022."},{"key":"3302_CR22","unstructured":"General Practitioners\u2019 Organisation (Praktiserende L\u00e6gers Organisation (PLO)). (2021) Collective agreement on general practice - Fee table, day time (Overenskomst om almen praksis - Honorartabel, dagtid)."},{"key":"3302_CR23","unstructured":"Association of Medical Specialists (Foreningen af Speciall\u00e6ger (FAS)). (2018) Collective agreement on specialist medical care between the Association of Medical specialists (FAS) and the Regions\u2019 wage and Tariff Board (RLTN) (Overenskomst om speciall\u00e6gehj\u00e6lp mellem Foreningen af Speciall\u00e6ger (FAS) og regionernes L\u00f8nnings- og Takstn\u00e6vn (RLTN))."},{"key":"3302_CR24","unstructured":"Danish Health Data Authority (Sundhedsdatastyrelsen). (2017) DRG rates 2017 (DRG-takster 2017). https:\/\/sundhedsdatastyrelsen.dk\/da\/afregning-og-finansiering\/takster-drg\/takster-2017. Accessed 11 May 2022."},{"key":"3302_CR25","volume-title":"Denmark\u2019s Convergence Programme 2021 (Danmarks Konvergensprogram 2021)","author":"Danish Ministry of Finance (Finansministeriet)","year":"2021","unstructured":"Danish Ministry of Finance (Finansministeriet). Denmark\u2019s Convergence Programme 2021 (Danmarks Konvergensprogram 2021). Denmark: The Danish Government; 2021."},{"key":"3302_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00043764-200201000-00004","volume":"44","author":"C Koopman","year":"2002","unstructured":"Koopman C, Pelletier K, Murray J, et al. Stanford Presenteeism Scale: Health Status and Employee Productivity. Journal of occupational and environmental medicine \/. Am Coll Occup Environ Med. 2002;44:14\u201320. https:\/\/doi.org\/10.1097\/00043764-200201000-00004.","journal-title":"Am Coll Occup Environ Med"},{"key":"3302_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hec.3052","volume":"24","author":"DI Rees","year":"2015","unstructured":"Rees DI, Sabia JJ. Migraine Headache and Labor Market Outcomes. Health Econ. 2015;24:659\u201371. https:\/\/doi.org\/10.1002\/hec.3052.","journal-title":"Health Econ"},{"key":"3302_CR28","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1177\/0333102418789072","volume":"38","author":"DC Buse","year":"2018","unstructured":"Buse DC, Lipton RB, Hallstr\u00f6m Y, et al. Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia. 2018;38:1622\u201331. https:\/\/doi.org\/10.1177\/0333102418789072.","journal-title":"Cephalalgia"},{"key":"3302_CR29","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, et al. Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain. 2018;19:82. https:\/\/doi.org\/10.1186\/s10194-018-0907-6.","journal-title":"J Headache Pain"},{"key":"3302_CR30","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10194-011-0321-9","volume":"12","author":"H Le","year":"2011","unstructured":"Le H, Tfelt-Hansen P, Skytthe A, et al. Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. J Headache Pain. 2011;12:157\u201372. https:\/\/doi.org\/10.1007\/s10194-011-0321-9.","journal-title":"J Headache Pain"},{"key":"3302_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353\u201365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006.","journal-title":"PharmacoEconomics"},{"key":"3302_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","volume":"23","author":"CK Cullum","year":"2022","unstructured":"Cullum CK, Do TP, Ashina M, et al. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain. 2022;23:61. https:\/\/doi.org\/10.1186\/s10194-022-01433-9.","journal-title":"J Headache Pain"},{"key":"3302_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(17)30083-2.","journal-title":"Lancet Neurol"},{"key":"3302_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","volume":"19","author":"A Angelis","year":"2018","unstructured":"Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight european countries. Eur J Health Econ. 2018;19:123\u201352. https:\/\/doi.org\/10.1007\/s10198-017-0871-0.","journal-title":"Eur J Health Econ"},{"key":"3302_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1751-5823.2010.00112.x","volume":"78","author":"J Bethlehem","year":"2010","unstructured":"Bethlehem J. Selection Bias in web surveys. Int Stat Rev. 2010;78:161\u201388. https:\/\/doi.org\/10.1111\/j.1751-5823.2010.00112.x.","journal-title":"Int Stat Rev"},{"key":"3302_CR36","doi-asserted-by":"publisher","unstructured":"Frost MH, Reeve BB, Liepa AM, et al. What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 10 Suppl. 2007;294\u2013S105. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00272.x.","DOI":"10.1111\/j.1524-4733.2007.00272.x"},{"key":"3302_CR37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/14737167.4.2.159","volume":"4","author":"JK Schmier","year":"2004","unstructured":"Schmier JK, Halpern MT. Patient recall and recall bias of health state and health status. Expert Rev Pharmacoecon Outcomes Res. 2004;4:159\u201363. https:\/\/doi.org\/10.1586\/14737167.4.2.159.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3302_CR38","volume-title":"The population\u2019s IT use (It-anvendelse i befolkningen)","author":"Statistics Denmark","year":"2020","unstructured":"Statistics Denmark. The population\u2019s IT use (It-anvendelse i befolkningen). Copenhagen: Statistics Denmark; 2020."},{"key":"3302_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/sim.4780110811","volume":"11","author":"R Lehr","year":"1992","unstructured":"Lehr R. Sixteen S-squared over D-squared: a relation for crude sample size estimates. Stat Med. 1992;11:1099\u2013102. https:\/\/doi.org\/10.1002\/sim.4780110811.","journal-title":"Stat Med"},{"key":"3302_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10194-010-0217-0","volume":"11","author":"LJ Stovner","year":"2010","unstructured":"Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289\u201399.","journal-title":"J Headache Pain"},{"key":"3302_CR41","doi-asserted-by":"crossref","unstructured":"Bidmon S, Eysenbach G. Gender differences in searching for Health Information on the internet and the virtual patient-physician relationship in Germany: exploratory results on how men and women Differ and why. J Med Internet Res 17:e156.","DOI":"10.2196\/jmir.4127"},{"key":"3302_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1474-4422(16)30293-9","volume":"16","author":"KG Vetvik","year":"2017","unstructured":"Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16:76\u201387. https:\/\/doi.org\/10.1016\/S1474-4422(16)30293-9.","journal-title":"Lancet Neurol"},{"key":"3302_CR43","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/pubmed\/fdm072","volume":"30","author":"K Juel","year":"2008","unstructured":"Juel K, Christensen K. Are men seeking medical advice too late? Contacts to general practitioners and hospital admissions in Denmark 2005. J Public Health (Oxf). 2008;30:111\u20133. https:\/\/doi.org\/10.1093\/pubmed\/fdm072.","journal-title":"J Public Health (Oxf)"},{"key":"3302_CR44","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/dme.12965","volume":"33","author":"C Sorts\u00f8","year":"2016","unstructured":"Sorts\u00f8 C, Green A, Jensen PB, Emneus M. Societal costs of diabetes mellitus in Denmark. Diabet Med. 2016;33:877\u201385. https:\/\/doi.org\/10.1111\/dme.12965.","journal-title":"Diabet Med"},{"key":"3302_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10072-020-04643-8","volume":"41","author":"G Allais","year":"2020","unstructured":"Allais G, Chiarle G, Sinigaglia S, et al. Gender-related differences in migraine. Neurol Sci. 2020;41:429\u201336. https:\/\/doi.org\/10.1007\/s10072-020-04643-8.","journal-title":"Neurol Sci"},{"key":"3302_CR46","doi-asserted-by":"publisher","unstructured":"Brusa P, Allais G, Rolando S, et al. Migraine attacks in the pharmacy: a gender subanalysis on treatment preferences. Neurol Sci 36 Suppl. 2015;193\u20135. https:\/\/doi.org\/10.1007\/s10072-015-2156-7.","DOI":"10.1007\/s10072-015-2156-7"},{"key":"3302_CR47","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/head.12150","volume":"53","author":"DC Buse","year":"2013","unstructured":"Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;53:1278\u201399. https:\/\/doi.org\/10.1111\/head.12150.","journal-title":"Headache"},{"key":"3302_CR48","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/jwh.2018.7274","volume":"27","author":"RA Schroeder","year":"2018","unstructured":"Schroeder RA, Brandes J, Buse DC, et al. Sex and gender differences in migraine-evaluating knowledge gaps. J Womens Health (Larchmt). 2018;27:965\u201373. https:\/\/doi.org\/10.1089\/jwh.2018.7274.","journal-title":"J Womens Health (Larchmt)"},{"key":"3302_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.labeco.2018.11.003","volume":"56","author":"Y Gallen","year":"2019","unstructured":"Gallen Y, Lesner RV, Vejlin R. The labor market gender gap in Denmark: sorting out the past 30 years. Labour Econ. 2019;56:58\u201367. https:\/\/doi.org\/10.1016\/j.labeco.2018.11.003.","journal-title":"Labour Econ"},{"key":"3302_CR50","unstructured":"The Danish Ministry of Health (Sundheds- og \u00c6ldreministeriet). (2020) Statutory order on the ethical treatment of Health Research Projects and Health Data Science Research Projects (Bekendtg\u00f8relse af lov om videnskabsetisk behandling af sundhedsvidenskabelige forskningsprojekter og sundhedsdatavidenskabelige forskningsprojekter)."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03302-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03302-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03302-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T07:02:59Z","timestamp":1688367779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03302-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3302"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03302-7","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lars Bendtsen (LB) and Sonja Antic (SA) have both served on the scientific advisory board for Novartis, AbbVie (Allergan), Teva, Lundbeck, and Eli Lilly. The work of Nikolaj Siersb\u00e6k (NS), L\u00e6rke Kilsdal (LK), and Christian Jervelund (CJ) was funded my Novartis (POP3 number DK2201120023). CJ is a Partner of Copenhagen Economics, who received funding from Novartis. Novartis was involved in the study\u2019s initiation and decision to submit it for publication, but neither Novartis and the other companies cited above nor anyone other than the authors had any involvement in the study\u2019s design, data collection, analysis and interpretation, or writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with the relevant guidelines and regulations. As this is a non-interventional study based on survey data that does not involve human biological material, ethical approval is not required from the Danish research ethics committee system according to Danish legislation (LBK nr 1338 af 01\/09\/2020) \u00a7\u00a014, stk. 2 [Act no. 1338 of 1 September 2020, Sect.\u00a014, subsection 2] []). Before initiating the survey for gathering RWD, the participants provided informed consent to participate in the survey. Data processing in the study was in accordance with the General Data Protection Regulation (nr 20\/8964).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NS, LK, and CJ are employees of Copenhagen Economics, which is one of the leading economics firms in Europe. Founded in 2000, we currently have more than 100 employees operating from our offices in Copenhagen, Stockholm, Helsinki, and Brussels. The Global Competition Review (GCR) lists Copenhagen Economics among the top 20 economic consultancies in the world, and has done so since 2006.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authours\u2019 information"}}],"article-number":"254"}}